Tech Company Financing Transactions

Azafaros Funding Round

On 5/13/2025, Azafaros raised $148 million in Series B funding from Forbion Growth Opportunities Fund II, Jeito Capital and BioGeneration Ventures.

Transaction Overview

Company Name
Announced On
5/13/2025
Transaction Type
Venture Equity
Amount
$148,000,000
Round
Series B
Proceeds Purpose
The company intends to use the funds to accelerate the development of its lead product, nizubaglustat, scheduled to enter Phase 3 studies for Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses later this year.

Company Information

Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Gooimeer 2-35
Naarden, 1411 DC
The Netherlands
Phone
Undisclosed
Email Address
Overview
Founded in 2018, Azafaros has leveraged on decades of discovery by professors Hans Aerts, Hermen Overkleeft, and Stan van Boeckel at Leiden University and the Academic Medical Center in the Netherlands. Expanding on their research and led by highly experienced industry experts in rare diseases, Azafaros is working on building a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families.
Profile
Azafaros LinkedIn Company Profile
Social Media
Azafaros Company Twitter Account
Company News
Azafaros News
Facebook
Azafaros on Facebook
YouTube
Azafaros on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Stefano Portolano
  Stefano Portolano LinkedIn Profile  Stefano Portolano Twitter Account  Stefano Portolano News  Stefano Portolano on Facebook
Chief Financial Officer
Henrik Nielsen
  Henrik Nielsen LinkedIn Profile  Henrik Nielsen Twitter Account  Henrik Nielsen News  Henrik Nielsen on Facebook
Chief Medical Officer
Christian Freitag
  Christian Freitag LinkedIn Profile  Christian Freitag Twitter Account  Christian Freitag News  Christian Freitag on Facebook
Chief Operating Officer
Silvia Ragno
  Silvia Ragno LinkedIn Profile  Silvia Ragno Twitter Account  Silvia Ragno News  Silvia Ragno on Facebook
Chief Scientific Officer
Kyle Landskroner
  Kyle Landskroner LinkedIn Profile  Kyle Landskroner Twitter Account  Kyle Landskroner News  Kyle Landskroner on Facebook
VP - Manufacturing
Kyung Na
  Kyung Na LinkedIn Profile  Kyung Na Twitter Account  Kyung Na News  Kyung Na on Facebook
VP - Regulatory Affairs
Anke Arnold-Tugulu
  Anke Arnold-Tugulu LinkedIn Profile  Anke Arnold-Tugulu Twitter Account  Anke Arnold-Tugulu News  Anke Arnold-Tugulu on Facebook


 

 

Browse more venture capital transactions:

Prev: 5/13/2025: Lignin Industries venture capital transaction
Next: 5/13/2025: Usul venture capital transaction

 

Share this article

 


About Our Venture Capital Transactions Database

We document every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary